Skip to main
We’re doing some system maintenance

Posts & Investments - #cancerkills

Invested in NexImmune
Close to Home, lost my kids father to cancer Sept 2020 at age 38 leaving 7 kids without a father. #investedforfuturefamilies #cancersucks #cancerkills #forthefuture #curecancer2022 •Neximmune, to Participate in, " The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel," on,“Expanding the Possible with Next-Generation Cell Therapies.” •Source: NexImmune, Inc. Jan.18th,2022 •About NexImmune: ~NexImmune is a: "Clinical-Stage Biotechnology Company." Developing a novel approach to IMMUNOTHERAPY designed to employ the BODY'S OWN T- CELLS to GENERATE a SPECIFIC, POTENT, and DURABLE IMMUNE RESPONSE. The backbone of NexImmune’s approach is a: "Proprietary Artificial Immune Modulation (AIM™) Nanoparticle Technology Platform." The AIM technology enables NexImmune to CONSTRUCT NANOPARTICLES that FUNCTION as SYNTHETIC DENDRITIC CELLS CAPABLE of DIRECTING a SPECIFIC T-CELL MEDIATED IMMUNE RESPONSE. AIM constructed nanoparticles EMPLOY NATURAL BIOLOGY to ENGAGE, ACTIVATE and EXPAND ENDOGENOUS T CELLS in ways that COMBINE anti-tumor attributes of antigen-specific PRECISION, POTENCY and LONG-TERM PERSISTENCE with REDUCED POTENTIAL for off-target toxicities. ++READ MORE DETAILS IN LINK! ++COMING MEETING JAN.21ST,2022 WORTH TAKING A LOOK AT! #helpeveryone #giveback #giveandgain #community #investinacause #2022 #growth #possibilitieshttps://www.globenewswire.com/news-release/2021/12/12/2350347/0/en/NexImmune-Announces-Preliminary-Phase-1-2-NEXI-002-Results-in-Patients-with-Multiple-Myeloma.html
0
0
Own your future.
Build your portfolio.
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.